By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
The brand has added a range of exciting new products especially formulated for oily skin.
The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.
The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Subscribe To Our Newsletter & Stay Updated
